Adjuvant Immunotherapy With Tumor Infiltrating Lymphocytes and Interleukin-2 in Patients With Resected Stage III and IV Melanoma
Authors:
- Laura RidolfiLaura Ridolfi
- Ruggero RidolfiRRRuggero Ridolfi
- Angela RiccobonARAngela Riccobon
- Franca De PaolaFPFranca De Paola
- Massimiliano PetriniMassimiliano Petrini
- Monica StefanelliMSMonica Stefanelli
- Emanuela FlaminiEFEmanuela Flamini
- Alessandra RavaioliARAlessandra Ravaioli
- Giorgio Maria VerdecchiaGVGiorgio Maria Verdecchia
- Giusto TrevisanGTGiusto Trevisan
- Dino AmadoriDADino Amadori
- 1 March 2003
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 26 (2) , 156-162
Abstract
Adoptive immunotherapy with tumor infiltrating lymphocytes (TIL) and interleukin (IL)-2 is reasonably effective in the treatment of patients with advanced melanoma. However, theoretically it should be of greater benefit as adjuvant therapy, especially in high-risk stages (resected stages III and IV). In a preliminary study, 25 patients (aged 23–72 years) with stage III–IV melanoma who underwent resection of metachronous metastases were reinfused with TIL cultivated and expanded in vitro with IL-2 from surgically removed metastases. IL-2 (starting dose 12 × 106 IU/m2) was co-administered as a continuous infusion according to West's scheme. A total of 8/22 (36.3%) evaluable patients were disease-free (DF) at a median follow-up of 5 years. DF survival (DFS) and overall survival (OS) rates were 44% and 37%, respectively, at 2 years, and 52% and 45% at 3 years. The CNS was the only site of disease recurrence in 57% of patients who relapsed. DF patients received a higher median dose of IL-2 than those who progressed (total dose 110 × 106 versus 86 × 106 IU/m2, respectively). The progressive reduction in IL-2 dosage allowed all patients to complete treatment without permanent grade 4 toxicity. Analysis of tumor immunosuppression factors in lymphocytes inside the tumor (TCR ζ and ε chains, p56lck, FAS, and FAS-ligand) confirmed that the immunologic potential of TIL, depressed at the time of metastasectomy, was significantly restored after in vitro culture with IL-2. Adoptive immunotherapy with TIL and IL-2 could improve DFS and OS, although further work is required to determine its role in the treatment of patients with high-risk melanoma.Keywords
This publication has 30 references indexed in Scilit:
- Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging SystemJournal of Clinical Oncology, 2001
- Escape of Human Solid Tumors from T–Cell Recognition: Molecular Mechanisms and Functional Significance1999
- The role of Fas/FasL in immunosuppression induced by human tumorsCancer Immunology, Immunotherapy, 1998
- Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanomaCancer, 1996
- Preventing abnormalities in signal transduction of T cells in cancer: the promise of cytokine gene therapyImmunology Today, 1996
- Clinical application of immunostimulatory gene transferEuropean Journal of Cancer, 1994
- Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytesCancer Immunology, Immunotherapy, 1994
- Localization of111Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with responseCancer, 1994
- Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A national biotherapy study group trialCancer, 1991
- Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trialsJournal of Immunological Methods, 1987